Dynavax Technologies Corporation

Ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2022 financial results. As a reminder, this conference call is being recorded. At the end of the company's prepared remarks, we will open the call for questions and provide specific instructions at that point. I would now like to turn the call over to Nicole Arndt, Senior Manager, Investor Relations. You may begin.

Thank you, operator. Good afternoon and welcome to the DynaVax fourth quarter and full year 2022 financial results and corporate update conference call.

In addition to our press release issued today, a supplementary slide presentation that accompanies today's call is available on the event section of our website. Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to, potential market sizes and market share, ACIP recommendations, impact, market trends, growth perspectives and rates, manufacturing plans, seasonality, financial guidance and trends, including revenue, profitability, and sufficiency of current capitalization, timing and results of clinical trial starts and data readouts, and potential future uses of CPG-1018 adjuvants. These statements involve risks and uncertainties, and our actual results may differ materially. These risks are summarized in today's press release and detailed in the risk factor section of our SEC filings, including today's annual report on Form 10-K. Our forward-looking statements speak as of today, and we undertake no obligation to update such statements. Joining me on the call today are Ryan Spencer, Chief Executive Officer, Don Casal, Senior Vice President of Commercial, Rob Jansen, Chief Medical Officer, and Kelly McDonald, Chief Financial Officer. I will now turn the call over to Ryan.